Sign in
SuspendedPhase 2

A Randomized, Double-blind Study of the Effects of Fenretinide Administered in Subjects With Obesity

Key facts

Who runs it
University of California, San Diego
Where
San Diego, United StatesSee the site
Trial code
Status
Suspended
Phase
Phase 2
People taking part
21 people enrolled
Started
Dec 2007
Expected to end
Jan 2099
Type of study
Interventional, 2 groupsOne group gets a placebo (a dummy treatment), for comparison.
Treatments tested
  • Fenretinide
  • Placebo
Record updated
10 February 2021
Why it stopped
This study was terminated due to expired drug with possibility of re-starting in the future.

Who can take part

Age
18 years to 65 years
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 3 criteriaShow less

Who can take part

  • BMI >30

Who cannot take part

  • Diabetes Requiring Medication
  • Poorly Controlled Co-Morbidities

Where in United States

  • University of California at San Diego HospitalsSan Diego, United States

About the trial

What the trial wants to find out

Many metabolic complications of obesity are a consequence of abnormal responses of the liver, muscle, and fat to insulin actions. Fenretinide may improve the effects of insulin, preventing metabolic complications.

The 2 groups in the trial

  • ATreatment being tested

    Subjects in this cohort will be given Fenretinide

    Treatment: Fenretinide

  • BPlacebo, for comparison

    Subjects in this cohort will be given placebo.

    Treatment: Placebo

Saves a reminder to your own calendar to look at this page again. Frontlight sends no messages and does not know you set it.

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
Phase 2 Study of the Assessment of the Insulin Sensitizing Activity of Fenretinide in Subjects With Insulin Resistance With BMI >30Kg/m2, and Liver Inflammation Related to Non-alcoholic Fatty Liver
Record updated
10 February 2021